The company's technology platform is based on advanced nanoparticles for the delivery and expression of therapeutic mRNA drugs in the endothelium, with their first development candidate, PAN004, representing a defined mRNA-LNP formulation for selective mRNA delivery and expression of a Tie2-agonist in the vascular endothelium of the lung. Pantherna aims to expand its pipeline with various novel mRNA-LNP candidates enabling the therapeutic use of mRNA beyond the vascular endothelium in distinct tissues such as skeletal muscle or immune cells.